We are live on
!
Find out more
Lexicon Pharmaceuticals
LXRX
LXRX
127 hedge funds and large institutions have $220M invested in Lexicon Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 24 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
236% more call options, than puts
Call options by funds: $547K | Put options by funds: $163K
88% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 24
2.5% more ownership
Funds ownership: 79.84% → 82.35% (+2.5%)
7% less funds holding
Funds holding: 137 → 127 (-10)
26% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 34
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less capital invested
Capital invested by funds: $453M → $220M (-$233M)
Holders
127
Holders Change
-10
Holders Change %
-7.3%
% of All Funds
1.67%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
25
Increased
45
Reduced
24
Closed
34
Calls
$547K
Puts
$163K
Net Calls
+$384K
Net Calls Change
-$1.68M
Top Buyers
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$17.3M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.65M |
| 3 |
Millennium Management
New York
|
-$2.2M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$1.26M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.18M |
